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The mystique of transplantation: 
biologic and psychiatric considerations 
Thomas E. Starzl M.D., Ph.D. 
Most major advances in medicine spring from discoveries in basic science 
and are therefore predictable, or at least logical. Organ transplantation was 
the supreme exception to the rule. Although the potential benefit of whole-
organ replacement in the absence of an immune barrier was dramatically 
demonstrated with the identical-twin kidney transplantation performed, in 
December 1954, by Joseph E. Murray (Nobel Laureate, 1990; Merrill et al. 
1956). this achievement only confirmed what already was known to be 
possible with identical-twin skin grafts (Padgett 1932; Brown 1937). In 1961, 
two months after receiving the 1960 Nobel Prize for research in immunology, 
Macfarland Burnet wrote in the New England Journal of Medicine that "much 
thought has been given to ways by which tissues or organs not genetically and 
antigenetically identical with the patient might be made to survive and 
function in the alien environment. On the whole, the present outlook is 
highly unfavorable to success ... " (Burnet 1961). 
This grim prospect, only a third of a century ago, faced the pioneer organ 
recipients whose courage in offering themselves up for human experimenta-
tion made it possible to crack the immunologic barrier (Starzl 1992). For 
three decades after this was done, there was no explanation for what had been 
accomplished. The resulting mystique of transplantation as well as the un-
predictable outcome of these procedures created a fertile emotional soil for 
psychiatric complications. Consequently, when the light of understanding 
was finally switched on in 1992, it was as much a spiritual as a scientific 
awakening. The acquisition of this insight exposed a seminal principle of 
allograft acceptance that is the same with all kinds of whole organs. 
The immunologic barrier: the one-way paradigm 
What was the immunologic barrier described in such pessimistic terms by 
Burnet, who saw no way that a transplanted histoincompatible organ could 
pass through the seemingly inviolate barrier of immunologic reactivity? In 
the identical-twin kidney transplantations, the problem was by-passed, but in 
all other cases, it was necessary to reckon with two potential complications, 
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either separately or together: rejection and graft-versus-host disease 
(GVHD). 
Rejection 
Although the details remain incomplete today, there was little mystery about 
the general meaning of rejection, following its elucidation in 1944 by 
Medawar (Nobel co-Laureate with Burnet 1960) as an immunologic event 
(Medawar 1944). This great contribution created the indelible image that 
transplantation involved a one-way immune reaction. Thus, a tissue (or 
organ) allograft was a defenseless island in a hostile recipient sea (Figure 
1.1(a». 
Tolerance 
In this context, an unsolved mystery of biology for nearly 40 years was how 
allografts could escape rejection without the recipient being crippled with 
immunosuppression. The description of acquired tolerance .by Billingham, 
Brent, and Medawar (1953, 1956) did not provide an answer. In their 
experimental model, immunocompetent adult spleen cells were injected in 
utero or perinatally into mice that had not yet evolved the necessary immu-
nologic maturity to reject them. The engrafted cells flourished and were 
thought to have in effect endowed the recipient with the donor immune 
system (donor leukocyte chimerism) (Figure l.l(b). 
Thereafter, the mice failed to recognize donor strain skin grafts or other 
tissues as alien (i.e. they had acquired tolerance). The switch in immunologic 
apparatus was consistent with the definition of transplantation immunology 
in terms of a unidirectional immune reaction (the "one-way paradigm"). 
Main and Prehn ( 1955) demonstrated the same tolerance outcome as Billing-
ham et al. in irradiated adult mice, whose cytoablated hematolymphopoietic 
cells were reconstituted with bone marrow instead of spleen cells. Thousands 
of subsequent tolerance induction experiments in animals. and eventually 
clinical bone marrow transplantation, seemingly depended upon a similar 
natural, or iatrogenically imposed. defenseless recipient state (Figure 1.1 (b». 
Graft-versus-host disease 
[t was recognized as early as 1957 in mouse (Billingham and Brent 1957) and 
chicken (Simonsen 1957) models that an immunologically active graft had a 
genetically controlled repertoire of immune reactivity comparable to that of 
the recipient. and could therefore turn the tables and reject the recipient. This 
was called graft-versus-host disease (GVHD). or alternatively "runt disease". 
The risk if the host was immunologically defenseless was roughly propor-
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tional to the extent of the major histocompatibility complex (MHC) differ-
ence between donor and recipient. Such disparities became measurable 
serologically in humans after identification of the human leukocyte antigens 
(HLAs) by Dausset (1990; Nobel Laureate 1980), Terasaki, and others whose 
reminiscences have been collected (Terasaki 1990). The complication of 
GVHD in rodent (Trentin 1957) and large animal irradiation chimera 
models (Mannick et al. 1959; Hume et a1. 1960; Rapaport et al. 1979; Thomas 
1991) forestalled for many years the clinical use of HLA mismatched bone 
marrow cells or other mature immunocytes, either for immunologic recon-
stitution with purely hematologic objectives or as a means of facilitating 
whole-organ graft acceptance. 
Clinical bone marrow transplantation 
The strategy that made possible the first successful clinical bone marrow 
transplantations in [968 was an extension of the rodent experiments, with 
similar histocompatibility-imposed restrictions (Mathe et al. 1963; Bach 
1968; Gatti et a1. 1968). After recipient cytoablation with total body irradi-
ation (TBl) or cytotoxic drugs (Figure l.1(b»), stable chimerism could be 
induced in humans by the infusion of donor bone marrow, but only if there 
was a good HLA match. Otherwise there was an intolerable incidence of 
lethal GVHD. Maintenance immunosuppression could frequently be stop-
ped in these patients, mimicking the kind of acquired immunologic tolerance 
originally described by Billingham et al. (1953, [956), and by Main and Prehn 
( [955). 
Clinical organ transplantation 
Ironically, surgeons and physicians had recorded thousands of successful 
human whole-organ transplantations (mostly kidneys) by the time bone 
marrow transplantation was finally accomplished. However, the conditions 
were dramatically different. First, continuous immunosuppression was 
needed, presumably for life. Second, success did not depend on HLA match-
ing. Third, the complication of GVHD was rare. Most immunologists were 
dumbfounded by these results. The inability to explain them detached 
workers in the whole-organ field from the scientific base enioyed bv bone 
marrow transplanters. Thus, further steps in the improvement of whole-
organ transplantation were largely the product of trial and error. To compre-
hend how this occurred requires a historical perspective. 
With total body irradiation 
Host preconditioning played an important role in the first six successful renal 
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Figure 1.1. Upper panels: One·way paradigm in which transplantation is conceived as 
involving a unidirectional immune reaction: host·versus·graft (HVG) with whole organs (a) 
and graft-versus-host (GVHl with bone marrow or other lymphopoietic transplants (b). 
Lower panels: Two-way paradigm with which transplantation is seen as a bidirectional and 
mutually cancelling immune reaction that is predominantly HVG with whole-organ grafts (cl. 
and predominantly GVH with bone marrow grafts and (d). 
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transplantations (defined as survival to more than one year) between 1959 
and 1962, one in Boston (Merrill et al. 1960) and five in France (Hamburger 
et al. 1962; Kuss et al. 1962). The recipients were prepared for operation with 
sublethal TBI, but without donor bone marrow; their own bone marrow 
recovered and one of these patients (in Paris) survived for 26 years. However, 
these were isolated successes in a sea of failures, and pessimism set in 
worldwide about the prospects of moving forward. 
Chemical immunosuppression 
The introduction, for human renal transplantation, of 6-mercaptopurine 
(6-MP) and its analogue azathioprine did not at first relieve the frustration. 
The clinical use of these drugs followed the demonstration of their im-
munosuppressive effects in extensive experimental studies, first with rodent 
skin transplantation (Meeker et al. 1959; Schwartz and Dameshek, 1960) and 
then with the canine kidney transplant models (Caine 1960, 1961; Zukoski, 
Lee, and Hume 1960; Murray et al. 1962). The drugs had been developed 
originally for their antileukemic effect by Elion and Hitchings (Nobel Laur-
eates, 1988; Elion, Bieber, and Hitchings 1955) and were first demonstrated 
to be immunosuppressive by Schwartz and Dameshek (1959). Although the 
kidney of the sixth patient treated by Murray with one of these myelotoxic 
drugs had the function of a non-related renal allograft for 17 months, the 
clinical results with chemical immunosuppression were generally poor at first 
(Murray et al. 1962, 1963), similar to those with TBI. 
The drug cocktail breakthrough 
The tidal wave of whole-organ cases began in earnest in 1962-3, when a 
characteristic cycle of convalescence was identified in which kidney rejection 
could be reversed surprisingly easily when prednisone was added to azathiop-
rine (double-drug therapy) (Starzl, Marchioro. and Waddell 1963). More 
importantly, the need later on for maintenance immunosuppression often 
declined as if the immune barrier had been lowered (Figure 1.2), and in 
occasional cases therapy could be stopped. Since then, the same sequence has 
been seen with all other organs transplanted and with all of the two-drug and 
more complex multiple agent immunosuppressive regimens. Drugs intro-
duced later were more potent and reliable in chaperoning the desired chain of 
events: antilymphocyte globulin (ALG) (Starzl et al. 1967), cyclosporine 
(Caine et al. 1979). and FKS06 (Starzl et al. 1989). Notwithstanding their 
diversity, all seemed in a fundamentally similar way to have allowed some-
thing to change in the host, the graft or both. But what? 
Deficiencies of the one-way paradigm 
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Figure 1.2. Pattern of postoperative events with whole-organ allograft acceptance. in the 
framework of the one-way paradigm. HVG. host·versus-graft. 
conceptualization of graft acceptance as a product of a unidirectional reac-
tion was reinforced with the introduction in 1963 of the one-way mixed 
lymphocyte reaction (Bach and Hirschhorn 1964; Bain. Vas. and Lowenstein 
1964). Although these and other in vitro techniques (the so-called minitrans-
plant models) generated increasingly sophisticated cellular and ultimately 
molecular studies of one-way immunologic reactions. the resulting plethora 
of new information resembled an exponentially expanding telephone direc-
tory. Most seriously, the flawed context lured successive generations of 
investigators into the trap of believing that tolerance induction for whole-
organ recipients (the "holy grail") lay in variations on the HLA-limiting 
strategy used for bone marrow transplantation. The strategy always included 
host preconditioning in preparation for a variety of donor leukocyte prepara-
tions. 
Cell-mediated immunity 
The inability of clinicians to explain what was going on with their patients did 
not dissuade them from developing their own voluminous literature which. 
was largely phenomenologic. An increasing number of transplant surgeons 
and physicians began to regard basic immunology as an interesting hobby, 
but one that was irrelevant to their practice. Meanwhile. most virologists and 
the majoritv of basic immunologists trying to understand rejection had 
shifted their efforts by the earlv 19iOs from whole-animal studies to T 
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Accessory Molecules 
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Figure 1.3. A schematic representation of the antiallograft immune response showing the 
cell surface proteins that participate in antigen recognition and signal transduction. the 
contribution of cytokines and the sites of action of the diverse agents that prolong graft 
survival. Antigen (allopeptide) recognition via the T cell receptor (TCR) and the role of 
accessory molecules can be blocked by monoclonal antibodies (MA), as can cytokine 
receptor expression. Deoxyspergualin (D) is believed to inhibit the function of 
antigen-presenting cells (APC). FKs06 (F. now tacrolimusl and cyclosporine (C) inhibit 
cytokine gene expression within T helper (TH) cells. whereas rapamycin (R) blocks the 
responses of T cells to interleukin (IL)-2. By inhibiting DNA synthesis, the antimetabolite 
drugs (A) act later than F. C or R to block lymphocyte proliferation. CT!.A4·lg (Cn is a new 
agent that blocks transmission of second signal (the B7-CD28) pathway essential for T cell 
activation. F/C. FKs06/CsA (cyclosporin A). (I) and (II) indicate major histocompatibility 
complex (MHC) antigens classes I and II. respectively_ 
lymphocyte-oriented cell culture (in vitro) systems. These labors were re-
warded by a Nobel Prize (to Baru; Benacerraf. 1980) and the Lasker Prize in 
Basic Science of 1995. which was shared by tour Americans and one Swiss 
(Doherty 1995; Unanue 1995; Zinkernagel1995). The conceptual model that 
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emerged provided an explanation of cell-mediated immunity (Figure 1.3). In 
the context of the one-way paradigm, the details of the putative allogeneic 
reaction (rejection) included its dependence on antigen-presenting cells, the 
necessity for a co-stimulatory molecule(s) (the two-signal concept of self/non 
self discrimination), an important role of accessory molecules, and cytokine 
control of clonal expansion ofT helper lymphocytes as well as of the cytotoxic 
T cells that are the agents of allograft destruction. The bewildering mass of 
details to which thousands of investigators had contributed over three dec-
ades (Taneway and Travers 1994) had long since overwhelmed most clinicians 
interested in applying the new information. 
Mechanisms of drug action 
However, the foregoing information allowed precise documentation of the 
surprising diversity of drugs with which long-term or permanent graft 
survival could be induced, no matter what the level of intervention in the 
immune reaction (Thomson and Starzl 1994). This is summarized in Figure 
1.3. Deoxyspergualin was said to alter the function of antigen-presenting 
cells, of which dendritic cells have been conceded to be the most important. 
The anti metabolite drugs (including azathioprine) prevented clonal expan-
sion of lymphocytes by inhibition of DNA synthesis. Cyclosporine and 
tacrolimus (FK506) disrupt signals from T cell receptor sites to the nucleus. 
Monoclonal antibodies (MAs) interrupt the immune reaction at the various 
specific targets (Figure 1.3), and rapamycin interdicts the effector events even 
after the secretion of the cytokine interleukin 2 (formerly called the "T cell 
growth factor"). The new immunosuppressive fusion protein CTLA4-Ig 
blocks the transmission of a "second signal" (the B7-CD28 pathway). All 
appear to be permissive of a natural event that became specific only by virtue 
of the presence of donor antigens. 
The immunologic barrier: the two-way paradigm 
Whole-organ transplantation 
Insight into what had happened to the pioneer organ recipients was obtained 
in retrospect bv studies, at the University of Pittsburgh nearly 30 years later, 
of a group of kidney and liver recipients from the earliest clinical trials at the 
Universitv of Colorado, who still had good function of their original grafts. 
Donor leukocytes of bone marrow origin that are part of the structure of all 
complex grafts ("passenger leukocvtes" (Snell 1957; Stein muller 1967)) were 
found in 1992 to have migrated from the organs and survived ubiquitously in 
the patients for up to three decades (Starzl et al. 1992, 1993), Thus, organ 
allogratt acceptance was associated with the cryptic persistence of a small 
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fragment of extramedullary donor marrow, including stem cells (depicted as 
a bone silhouette in Figure l.l(c)). These cells had been assimilated into the 
overwhelmingly larger immunologic network of the host. The leukocyte 
movement was in both directions, with small numbers of residual donor 
leukocytes (microchimerism) in both the graft and host. 
The discovery was instinctively understood by most patients to whom it 
was explained, and it had a surprisingly great emotional impact. The point 
was not lost that the physical intimacy of the donor to the recipient was 
greater than anyone had ever imagined. It was closer and more lasting than 
that of a gestational fetus with its mother. The woman applying lipstick in the 
morning was touching that unknown cadaveric male donor of 30 years ago 
whose live cells were everywhere in her own tissue. She was not the recipient 
of an organ only. The realization was usually moving, and it was invariably 
sobering. 
Scientifically, a revision of transplantation immunology was mandated in 
which the immunologic confrontation following whole-organ transplanta-
tion could be seen as a bidirectional and mutually cancelling (graft-versus-
host (GVH) as well as host-versus-graft (HVG)) interaction (Figure 1.4), 
provided the two participants in the David (donor)/Goliath (recipient) 
mismatch could survive the initial confrontation. Clinically, but not in 
several animal models, this outcome requires an umbrella of immunosup-
pression that protects both cell populations equally (Figure l.l(c)). 
Understanding the amplification device by which the small number of 
donor cells can so profoundly affect the immunologic vision of, and eventu-
ally be assimilated by, the vast recipient army against which it is arrayed is of 
intense scientific interest. The chimeric leukocytes are multilineage (Starzl et 
a1. 1992, 1993; Demetris et al. 1993; Qian et al. 1994). However, the antigen-
presenting dendritic cells (DCs) of Steinman and Cohn (1973; Steinman 
1991) are thought to be the key to the reciprocal tolerogenic process because 
they can modify in both cell populations the expression of cell interaction, 
MHC, and adhesion molecules. All of these interactions determine how 
antigen signals are responded to by T cells (Steinman 1991). Evidence 
confirming the original observations, allowing a more complete understand-
ing of the tolerogenic mechanisms, has been summarized recently (Starzl and 
Zinkernagel 1998). 
Historical enigmas 
With the two-way paradigm, the reason for virtually every previously unex-
plained experimental or clinical observation after whole-organ transplanta-
tion became either transparent, or at least susceptible to experimental inquiry 
(Starzl et al. 1992, 1993). [t could be understood why organ grafts are 
inherently tolerogenic and therefore "accepted" by the recipient. With the 
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Figure 1-4. The pattern of convalescence after either organ or bone marrow transplantation 
in the framework of the two-way paradigm. HVG, host-versus-graft; GHV, 
graft-versus-host. 
two-way mutual cancellation implicit in this concept. the loss or blunting of 
an HLA-matching effect was comprehensible. With each further level of 
histoincompatibility, the reciprocal effect apparently escalates both ways 
under the umbrella of an effective immunosuppressant (Figure 1.5). The 
consequent dwindling of the matching effect as donor-specific and recipient-
specific nonreactivity evolves accounts for "blindfolding" of the expected 
HLA intluence_ 
In addition to explaining why the HLA-matching effect is mitigated, the 
mutual functional cancellation of the two cell populations explains why 
GVHD does not develop after liver. intestinal, multivisceral, and heart-lung 
transplantation, despite the heavy lymphoid content of those organs. The 
safety of these procedures depended on leaving the recipient immunologic 
system intact until the time of transplantation. 
Augmentation of spontaneous chimerism 
Because the acquisition of immunologic tolerance in the originally Billin-
gham-Brent-Medawar and derivative models depended on donor leukocyte 
(splenocyte or bone marrow) infusion (Billingham et al. 1953, 1956; ~Dlain 
and Prehn 1955), sporadic attempts had been made to improve organ 
allograft outcome by infusing adiuvant donor bone marrow (Monaco, Clark, 
and Brown 1976; Barber et al. 1991) or blood (Salvatierra et al. 1980; 
Anderson, Sicard. and Etheredge 1982; Sollinger et al. 1984). These were 









Figure 1.5. Explanation for the loss of an HLA·matching effect with whole·organ 
transplantation. R.; immunosuppression. 
hampered by the assumption that the infused cells would be destroyed unless 
there was recipient preconditioning with irradiation or myelotoxic drugs. In 
turn. the prospect of recipient cytoablation engendered anxiety about caus-
ing GVHD. Most importantly. the appropriate timing of the cell infusions 
was controversial. Consequentlv. the strategy of donor leukocyte augmenta-
tion never gained a clinical foothold. 
The discoveries of leukocyte chimerism in 1992 (Starzl et al. 1992. 1993) 
exposed a perioperative window of opportunity during which unaltered 
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Figure 1.6. Iatrogenic augmentation of the graft·versus·host (GVH) component of the 
two·way paradigm by infusing 3 108 to 6 10" /kg unaltered donor bone marrow cells at 
the same time as heart or other whole·organ transplantation. When the recipient is not 
cytoablated. there is essentially no risk of GVHD. 
HLA-incompatible bone marrow or donor-specific blood transfusion was 
predicted to be safe without recipient preparation or any other deviation 
from the generic noncytoablative practices of immunosuppression for 
whole-organ transplantation that had evolved over the years from the orig-
inal azathioprine-prednisone formula (Starzl et al. 1963). The validity of this 
expectation was verified recently in nonpreconditioned recipients of cadaver-
ic kidneys, livers, hearts, and lungs who were given adjuvant bone marrow 
cells at 3 x lOx to 5 x 10M Ikg at the same time as organ transplantation under 
standard tacrolimus-prednisone treatment (Figure 1.6) (Fontes et al. 1994). 
Chimerism estimated to be > 1000 times that occurring in conventional 
whole-organ recipients was reliably and safely produced and sustained. The 
persistent blood chimerism (usually > 1 %), trend toward donor specific 
nonreactivity, and high rate of patient and graft survival, have marked these 
bone marrow augmented recipients as an advantaged cohort. They are the 
first patients to undergo HLA-mismatched cadaveric organ transplantation 
with the hope of eventually becoming drug free. The process of tolerance 
induction and drug weaning is expected to take 5 to 10 years, but in some the 
drug-free state may never be attainable. 
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The drug-free state 
The concept that organ transplantation is equivalent to a small bone marrow 
transplantation (and that this explains allograft acceptance) has been con-
firmed and greatly extended in animal models, principally by Qian et al. 
(1994) and by Demetris et al. (1993) and Murase et al. (1995). The cardinal 
principle is that the long and continuing survival of an organ allograft means, 
by definition, that donor leukocyte chimerism is present. Failure to demon-
strate chimerism in such recipients connotes an inadequate search (Murase et 
al. 1995). 
However, donor leukocyte chimerism is merely a prerequisite for graft 
acceptance (Starzl et al. 1992). Is the demonstration of chimerism an indica-
tion to stop immunosuppression? Emphatically no! However, knowledge of 
the chimerism mechanism makes it clear why drugs can in fact be stopped 
permanently after organ transplantation in some cases. In late 1995, 12 (28%) 
of the 43 longest surviving liver recipients in the world (14 to 26 years) have 
been off drugs for 1 to almost 19 years. Complementing these observations, 
Ramos et al. (1995) have reported a prospective weaning trial for liver 
recipients, limited for the most part to patients who were 5 to 10 years 
post-transplantation. Freedom from rejection for at least 5 years was a 
prerequisite for admission to the trial. which has expanded to 80 patients. 
Forty-four (55%) of these liver recipients have come off drugs completely or 
have moved uninterruptedly in that direction; in 22 whose weaning is 
complete. the drug-free time averages O~ years. Weaning is being carried out 
more slowly now than at the beginning of the trial because of a 30% incidence 
of rejection. It was evident that the vast majority of the 80 liver recipients had 
been at a level of immunosuppression higher than they needed. It is more 
dangerous to attempt weaning after kidney transplantation. and we rarely 
recommend this. However, five of our longest-surviving living related kidney 
recipients have been off all immunosuppression for 2 to 30 years. A recent 
report has documented these results (Mazariegos et al. 1997). 
Rejection after drug discontinuance 
The benefits of weaning for organ recipients are obvious. However. it is 
equally important to recognize that there was a 30% overall risk of rejection 
in the prospective liver trial. Successful weaning was achieved consistently 
only in the patients being weaned from an azathioprine-prednisone regimen 
or from monotherapy with tacrolimus (Ramos et al. 1995). When weaning 
failed. biopsy-proved reiection was diagnosed I to 29 months after drug 
withdrawal was started and usually was classed histopathologically as mini-
mal to mild. Restoration of the previous baseline immunosuppression was 
the only adiustment required in most cases. but tour patients with moderate 
or severe reiection required rescue treatment with tacrolimus: this included 
SOLID ORGAN 
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Figure 1.7. The growth. as separate disciplines. of bone marrow (right) and whole-organ 
transplantation (left) from the seed planted by Peter Medawar during World War II. It was 
recognized in 1992 that these seemingly disparate disciplines were mirror images caused 
by different treatment strategies as explained in the text. GVHD. graft-versus-host disease. 
one who became jaundiced, with a peak bilirubin of 12 mg%. Although no 
patients or grafts were lost in our trial. Sandborn et al. (1994) encountered 
rejection in 6 of 12 patients at the Mayo Clinic whose rapid weaning from 
cydosporine-based triple drug therapy was attempted after only three post-
transplant years; two of the six died. It would be foolhardy to ignore such a 
warning. 
Bone marrow transplantation 
When it was discovered that successful whole-organ transplantation was 
associated with spontaneous chimerism, it was realized that the seemingly 
vast gap between the bone marrow and whole-organ transplantation fields 
reHected entrenched differences in treatment strategy l Figure 1.7). The mu-
tually censoring immunologic limbs were being left intact with organ trans-
plantation, whereas the recipient limb was deliberately removed (cytoabla-
tion) in preparation for bone marrow grafting procedures. Although it was 
long assumed that the entire recipient immune system had been eliminated 
with successful bone marrow transplantation (Figure 1.1 (b)), a trace popula-
tion of recipient leukocytes has been detected with sensitive techniques in the 
blood of almost all such patients (Przepiorka et al. 1991; Wessman et al. 
1993 ). 
These bone marrow recipients were in fact mirror images of those 
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successfully bearing whole-organ allografts. the difference being that their 
own residual leukocytes rather than those of the donor constituted the trace 
population. Under both circumstances. other findings such as the appearance 
of veto and suppressor cells. enhancing antibodies. and changes in cytokine 
profile could be construed as by-products, of and accessory to. the seminal 
event of the mutual cell engagement (Figure 1.1 (c) and (d)). 
Conclusions 
In this chapter, a generic explanation has been provided for what has been 
one of the most remarkable and in some respects conceptually enigmatic 
developments in the history of medicine. Successful engraftment of the 
kidney (Merrill et a1. 1960). pancreas (Lillehei et al. 1970), liver (Starzl et al. 
1968). heart (Barnard 1968). lung (Derom et al. 1971). and multiple abdomi-
nal viscera (Starzl et al. 1989) intestine (Goulet et al. 1992) were empirical 
achievements, accomplished largely by dogged trial and error. Each organ-
defined specialty has had its historians who track their story back to one of 
the foregoing milestones where the trail goes cold. The reason is that such 
accounts have been preoccupied with a succession of events rather than the 
biologic principles that are applicable to all organ allografts. Escape from this 
intellectual cui de sac became possible with the discovery in 1992 that donor 
leukocyte chimerism occurs spontaneously after organ transplantation, and 
the development of evidence that this is the basis of graft acceptance. 
Beacons of understanding shine forward as well as back. Comprehension 
of the history of transplantation in terms of the two-way paradigm (Starzl 
and Demetris 1995) provides the conceptual means to devise better treatment 
strategies, including the achievement of drug-free tolerance. If the goal of 
xenotransplantation is attained (and it may be soon), the same ubiquitous 
mix of two genetically different leukocyte populations as that following 
allotransplantation will be a necessary condition. Although the diffuse dis-
tribution of donor leukocytes in organ recipients is not thought to affect 
central nervous system changes, the emotional and psychiatric implications 
of creating animal/human genetic composites via xenotransplantation can-
not be taken lightly. 
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